Dr. Daniel A Albert Investigator

Rheumatology NPI1386670636

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$12,245.49
from 4 payments in the last 6 years

Total Cash or Cash Equivalent

$12,164.72
from 2 payments in the last 6 years

Total In-kind Items & Services

$80.77
from 2 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
12/16/2021 General (Non-Research) In-kind items and services Education $79.99 Details
Payment from SANOFI-AVENTIS U.S. LLC
Payment Record ID 843761939
12/31/2017 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12085.36 Details
Payment from PFIZER INC.
Payment Record ID 506163641
05/01/2017 General (Non-Research) In-kind items and services Education $0.78 Details
Payment from Retrophin, Inc.
Payment Record ID 485872063
02/27/2017 Research Cash or cash equivalent $79.36 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
Payment Record ID 478900123